Introduction
============

Ischaemic heart disease (IHD) and its most grave consequence, namely myocardial infarction (MI), remain among the most common public health threats worldwide. High and medium income countries are strongly affected, with the yearly rate of MI throughout Europe ranging from 90 to 312 per one hundred thousand individuals yearly and a high number of myocardial infarction episodes with ST elevation (STEMI). In Poland cardiovascular disease (CVD) remains a primary public health issue as well, being the leading cause of death (45.6% in 2008). Among males below 59 years of age CVD-associated mortality was three-fold higher, with gender-related differences becoming insignificant in older individuals \[[@R1]\].

Extensive, multicentre research has identified an array of "classical" MI risk factors with age, smoking, hypercholesterolaemia, hypertension, type 2 diabetes and positive IHD family history being the most common \[[@R2]\]. It must be noted that genetic factors should also be considered, as indicated by family and gene variant association studies performed on large groups and high numbers of genetic markers \[[@R3]-[@R5]\]. Of these, high throughput single nucleotide polymorphism (SNP) studies resulting in the identification of risk-associated alleles proved to be of the highest value \[[@R4], [@R6]\], with results validated by risk-allele targeted association studies \[[@R7], [@R8]\].

For this study a genetic variant of a vesicle-associated membrane protein (VAMP), previously unstudied in the Polish population, was selected. Vesicle-associated membrane protein proteins play a crucial role in the regulatory mechanisms of platelet secretory function \[[@R9]\]. It has been demonstrated that cellubrevin (VAMP-3) and endobrevin (VAMP-8) form soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes in human platelets and mediate granule secretion \[[@R10], [@R11]\]. VAMP-8 gene polymorphism in the 3' untranslated region (accession number rs 1010) has been identified as one of the risk factors for early-onset MI in a large case-control study analysing 11 647 human SNPs \[[@R6]\]. Associations between VAMP-8 gene polymorphisms and *in vitro* platelet functions were studied, but did not give conclusive data on the polymorphism-related mechanism of platelet dysfunction \[[@R12], [@R13]\].

The aim of this research was to analyse an association between risk of early onset of MI (\< 55 years of age) among male subjects and VAMP-8 gene polymorphism (rs 1010). This is the first study on Polish subjects and in the North-European area.

Material and methods
====================

Subjects
--------

The study protocol was approved by the local Ethical Committee with all patients voluntarily consenting to participate in the research.

For the study group 171 male patients (mean age of 55.7 ±9.8 years) were enrolled. All cases had a history of MI and underwent interventional procedures (coronary angiography) at the Department of Cardiology, Pomeranian Medical University, Szczecin. The group was divided into early-onset MI (infarction below the age of 55 years, *n* = 103) and late onset MI subgroups (infarction at the age ≥ 55 years, *n* = 68). Resting ECG was performed in all cases; full medical and treatment history including smoking status was obtained and body mass index was calculated. Biochemical analyses in this group included determination of serum total cholesterol and triglyceride concentrations prior to the angiography. For genetic analyses whole blood samples were collected on EDTA anticoagulant. All subjects were treated according to the IHD treatment guidelines with ACE inhibitors, statin, β-blockers, and aspirin. The study protocol was approved by the local Bioethics Committee.

Genotyping
----------

The QIAamp DNA Blood Mini Kit (QIAgen, Hilden, Germany) was used to extract genomic DNA from blood samples. The extraction was performed by following the manufacturer's protocol. DNA was re-suspended in 200 µl of AE buffer (QIAgen, Hilden, Germany) and stored at 4°C for further analyses. Identification of VAMP-8 A/G gene polymorphism was performed by a PCR method, previously described by Shiffman, using the following primers: sense: 5´- GGG GGC TCC AAC TTT CTT CTC C and antisense 5´- CTT TGC CAC TGG TGC CTT CTC TTA \[[@R6]\]. RFLP of the PCR product with the restriction enzyme Mae II was performed; for the A allele the final product of 494 base pairs (b.p.) remained undigested, while the G variant gave digested products of 328 b.p. and 166 b.p. Products were electrophoresed in agarose gel stained with ethidium bromide and analysis results were recorded digitally.

Statistical analysis
--------------------

Allele and genotype frequencies among cases and controls were compared with values predicted by the Hardy-Weinberg equilibrium. Odds ratios (OR) were calculated as a measure of association between genotype and MI. For each OR, we calculated the 2-tailed probability value and 95% CI. Odds ratios and p values were calculated separately for A and G alleles.

A value of *p* \< 0.05 was considered as indicative of a statistically significant effect. Logistic regression models were designed to evaluate the importance of risk factors in MI.

Results
=======

Clinical and laboratory characteristics of early and late-onset MI subgroups are presented in Table [I](#T1){ref-type="table"}. Power of the analysis was supported by the strong statistical difference observed for the age criterion, applied after division into the subgroups. Additionally, lipid concentrations were higher in the early-onset MI group, while a notably higher number of hypertensive individuals was observed in the late onset MI group. No significant differences concerning smoking or body mass index were observed between the subgroups.

Allele and genotype distributions for both subgroups are presented in Table [II](#T2){ref-type="table"}. Distribution of individual AA, AG and GG genotypes did not differ significantly between the subgroups, while A allele frequency was significantly higher among subjects with early-onset MI (below the age of 55 years) when compared to late-onset MI (above 55 years). Relative risk (RR) of early-onset MI was demonstrated to be higher in individuals carrying the A allele. RR was calculated for both the individual A allele (difference statistically significant, *p* = 0.029) and A allele containing genotypes (statistical differences not significant); in our study A was proven to be an early-MI risk associated allele.

Additionally, diagnosis of hypertension, smoking status, BMI, total cholesterol and triglyceride levels were correlated by logistic regression with frequency of the investigated alleles and genotypes, but no association between risk genotypes and traditional risk factors was observed.

Discussion
==========

In this study the hypothesis that VAMP-8 rs1010 single nucleotide polymorphism is associated with increased risk of early-onset myocardial infarction was tested. This SNP was selected after a review of existing research data, in which it has been defined as one of the risk alleles for coronary heart disease, early-onset MI and ischaemic stroke in Caucasian populations \[[@R3], [@R7]\]. The decision to limit our study to male cases only was based on the genetic risk analysis performed in the study by Shifmann to maximize the possibility to obtain a valid result \[[@R6]\]. Moreover, cardiovascular disease incidence among young men is higher than among young women and therefore genetic risk factor identification is of higher importance in this group.

Influence of the VAMP-8 rs1010 variants was proven to be additive, and was included in a coronary heart disease genetic risk score model for the *Atherosclerosis Risk in Communities*study \[[@R14]\]. As most of the studies so far have been performed in the United States, our study aimed to confirm the risk association described above in the Polish population, which could be representative of North-European populations. Extensive genetic research has been published in the field of genetic factors associated with early-onset coronary artery disease \[[@R15], [@R16]\], but precise identification of single nucleotide risk variants remains infrequent.

VAMP-8 rs1010 SNP was associated with early-onset MI in our study, with the A variant identified as the risk allele. It must be noted that such a finding is discordant with the data published before, where the G allele was indicated to be associated with enhanced risk in the large-scale SNP genotyping study performed by Shifmann in order to identify MI early-onset genetic risk factors \[[@R6]\]. That study was performed on a group of American Caucasians with MI diagnosed at age \< 55 among male subjects and \< 60 for females; the odds ratio (OR) related to the disease was 1.26 for the G risk allele for the entire group, while the estimated risk for this variant was even higher for males (OR 1.97). However, this analysis was unadjusted for age and diabetes. Additionally, in the aforementioned *Atherosclerosis Risk in Communities*study a high genetic risk score, defined as the presence of five single nucleotide polymorphisms including VAMP-8 rs1010, was associated with increased risk of incident coronary heart disease (CHD) after adjusting for traditional risk factors. In this study an association between the G risk allele and myocardial infarction was also confirmed \[[@R3], [@R14]\]. These association analyses were performed for white populations, but no variable of early-onset MI was analysed.

On the other hand, van der Net *et al*., in an association study performed on patients with familial hypercholesterolaemia, did not confirm the findings of increased risk related to the VAMP-8 rs1010 variants \[[@R8]\]. This study was performed on relatively young (mean age of 48.8 years) Caucasian Europeans and might indicate a possible association between coronary heart disease and MI risk with this SNP.

It must also be noted that the sample analysed in our study is a Caucasian population from the north-western region of Poland, which due to the post-war migration is highly likely to be genetically diverse. The VAMP-8 allelic frequency is therefore highly likely to be similar in the whole of Poland. A strong influence of classical, environmental CVD and MI risk factors in the Polish population has been previously confirmed \[[@R17]\] but this genetic, risk-allele based study contributes to the knowledge concerning the genetic epidemiology of CAD.

A limitation of the study is related to the fact that the occurrence of classical risk factors in the Polish population is high and thus they may play a greater role in atherosclerosis pathogenesis than genetic factors. However, further gene association studies are necessary for younger populations, with shorter time of exposure to MI-promoting environmental factors, such as smoking, diet or obesity, where genetic risk factors would be of even greater influence and importance.

In conclusion, VAMP-8 rs1010 gene variants are related to the risk of early-onset myocardial infarction, with further gene association studies necessary for confirmation of its exact influence on coronary artery disease.
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###### 

Baseline clinical and laboratory characteristics of study patients

  Variable                      MI \< 55     MI ≥ 55      Value of *p*
  ----------------------------- ------------ ------------ --------------
  Age of MI                     47.3 ± 5.2   63.4 ± 6.2   0.001
  Hypertension\[%\]             44           60           0.033
  Smofkers \[%\]                61           54           0.380
  Body mass index \[kg/m^2^\]   27.2 ± 3.4   27.0 ± 3.6   0.667
  Total cholesterol \[mg/dl\]   230 ± 40     218 ± 39     0.056
  Triglycerides \[mg/dl\]       201 ± 157    158 ± 74     0.035

###### 

VAMP-8 polymorphism associated risk of myocardial infarction in Polish males

  Genetic variant   MI \< 55, *n*(%)   MI ≥ 55, *n*(%)   OR~A~ (95% CI)     Value of *p*   OR~G~ (95% CI)     Value of *p*
  ----------------- ------------------ ----------------- ------------------ -------------- ------------------ --------------
  AA + AG           93 (90.3)          57 (83.8)         1.63 (0.63-4.23)   0.309          --                 --
  AA                49 (47.6)          21 (30.9)         2.24 (0.78-6.41)   0.128          1                  --
  AG                44 (42.7)          36 52.9)          1.37 (0.50-3.75)   0.531          0.66 (0.32-1.35)   0.247
  GG                10 (9.7)           11 (16.2)         1                  --             0.45 (0.16-1.28)   0.128
  AG + GG           54 (52.4)          47 (69.1)         --                 --             0.60 (0.31-1.18)   0.136
  A                 142 (68.9)         78 (57.4)         1.65 (1.03-2.65)   0.029          --                 --
  G                 64 (31.1)          58 (42.6)         --                 --             0.61 (0.38-0.97)   0.029

*All findings concerning genotypes were adjusted for BMI, smoking, hypertension, cholesterol and triglyceride concentrations*
